Adrian Gottschalk - Foghorn TherapeuticsInc CEO President
| FHTX Stock | USD 5.56 0.38 6.40% |
CEO
Adrian Gottschalk is CEO President of Foghorn TherapeuticsInc
| Age | 48 |
| Address | 500 Technology Square, Cambridge, MA, United States, 02139 |
| Phone | 617 586 3100 |
| Web | https://foghorntx.com |
Adrian Gottschalk Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adrian Gottschalk against Foghorn TherapeuticsInc stock is an integral part of due diligence when investing in Foghorn TherapeuticsInc. Adrian Gottschalk insider activity provides valuable insight into whether Foghorn TherapeuticsInc is net buyers or sellers over its current business cycle. Note, Foghorn TherapeuticsInc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Foghorn TherapeuticsInc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adrian Gottschalk over three months ago Acquisition by Adrian Gottschalk of 300000 shares of Foghorn TherapeuticsInc subject to Rule 16b-3 | ||
Adrian Gottschalk over six months ago Bona fide gift to Adrian Gottschalk of 63000 shares of Foghorn TherapeuticsInc subject to Section 16 | ||
Adrian Gottschalk over six months ago Bona fide gift to Adrian Gottschalk of 300000 shares of Foghorn TherapeuticsInc subject to Section 16 |
Foghorn TherapeuticsInc Management Efficiency
The company has return on total asset (ROA) of (0.2046) % which means that it has lost $0.2046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7038) %, meaning that it created substantial loss on money invested by shareholders. Foghorn TherapeuticsInc's management efficiency ratios could be used to measure how well Foghorn TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.34 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Foghorn TherapeuticsInc's Debt To Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 0.84 in 2024, whereas Total Assets are likely to drop slightly above 280.8 M in 2024.Similar Executives
| Found 1 records | CEO Age | ||
| Markus MD | Monte Rosa Therapeutics | 52 | |
Management Performance
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.2 |
Foghorn TherapeuticsInc Leadership Team
Elected by the shareholders, the Foghorn TherapeuticsInc's board of directors comprises two types of representatives: Foghorn TherapeuticsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foghorn. The board's role is to monitor Foghorn TherapeuticsInc's management team and ensure that shareholders' interests are well served. Foghorn TherapeuticsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foghorn TherapeuticsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saurabh Sewak, Vice Development | ||
| Karin Hellsvik, Corporate VP | ||
| Adrian Gottschalk, CEO President | ||
| Stephen DiPalma, Treasurer CFO | ||
| Allan MD, Chief Officer | ||
| Alfonso MD, Chief Officer | ||
| Gerald Md, Founder Board | ||
| Fanny Cavalie, Chief Officer | ||
| Carlos Costa, Chief Officer | ||
| Ben Strain, VP Communications | ||
| Michael LaCascia, Chief Officer | ||
| Steven Bellon, Chief Officer | ||
| MPH MD, Chief Officer |
Foghorn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foghorn TherapeuticsInc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (2.74) % | ||||
| Operating Margin | (5.58) % | ||||
| Current Valuation | 73.09 M | ||||
| Shares Outstanding | 42.59 M | ||||
| Shares Owned By Insiders | 24.78 % | ||||
| Shares Owned By Institutions | 62.28 % | ||||
| Number Of Shares Shorted | 1.32 M | ||||
| Price To Book | 10.71 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn TherapeuticsInc guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Foghorn Stock analysis
When running Foghorn TherapeuticsInc's price analysis, check to measure Foghorn TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn TherapeuticsInc is operating at the current time. Most of Foghorn TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Foghorn TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn TherapeuticsInc's price. Additionally, you may evaluate how the addition of Foghorn TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Foghorn TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Foghorn TherapeuticsInc. If investors know Foghorn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Foghorn TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.20) | Revenue Per Share 0.805 | Quarterly Revenue Growth (0.05) | Return On Assets (0.20) | Return On Equity (4.70) |
The market value of Foghorn TherapeuticsInc is measured differently than its book value, which is the value of Foghorn that is recorded on the company's balance sheet. Investors also form their own opinion of Foghorn TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Foghorn TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Foghorn TherapeuticsInc's market value can be influenced by many factors that don't directly affect Foghorn TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Foghorn TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Foghorn TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Foghorn TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.